DIA 48th Annual Meeting
Click here to go to the previous page
The Impact of Social Media on Product Promotion and Pharmacovigilance
Track
:
Track 14: Clinical Safety and Pharmacovigilance
Program Code:
116
Date:
Monday, June 25, 2012
Time:
10:00 AM to 11:30 AM
EST
CHAIR
:
Julie Zawisza, FDA, United States
PRESENTER
(S):
Thomas Abrams, FDA, United States Paul Savidge, Bristol-Myers Squibb Company, United States Elizabeth Garrard, Drug Safety Alliance, Inc., United States Gerald Dal Pan, FDA, United States
Description
Social media creates challenges and opportunities for the promotion and safety of drugs and other medical products. FDA and industry are working to optimize truthful product information and ways to gather adverse event data utilizing this resource
Learning Objectives:
Describe FDA's efforts to ensure fair, balance promotion with social media
Explore the effects of social media on FDA's efforts to monitor safety
Discuss challenges social media present to the pharmaceutical industry's efforts to ensure fair and balanced communication about its products.
Learning Objectives:
Describe FDA's efforts to ensure fair, balance promotion with social media
Explore the effects of social media on FDA's efforts to monitor safety
Discuss challenges social media present to the pharmaceutical industry's efforts to ensure fair and balanced communication about its products.
This session is a part of:
Handout Online
